AngioDynamics (NASDAQ:ANGO) Announces Earnings Results, Beats Estimates By $0.07 EPS

AngioDynamics (NASDAQ:ANGO) released its earnings results on Thursday. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07, FiscalAI reports. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The company had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

AngioDynamics Price Performance

Shares of ANGO opened at $14.19 on Thursday. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29. The company has a 50 day simple moving average of $15.46 and a two-hundred day simple moving average of $13.11. The firm has a market cap of $596.69 million, a P/E ratio of -16.31 and a beta of 0.30.

Insider Activity at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, HC Wainwright increased their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Quarterly results exceeded expectations: AngioDynamics reported revenue of $80.9 million, above the $80.5 million consensus estimate, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, and the GAAP net loss narrowed to $7.1 million from $10.9 million. AngioDynamics Fiscal 2027 First-Quarter Financial Results
• Positive Sentiment: Medical technology growth was strong: Med Tech sales rose 13.2% to $39.9 million, led by Auryon sales growth of 14.7% and NanoKnife sales growth of 29.0%. Gross margin also expanded 410 basis points to 59.4%, indicating improved operating performance.
• Positive Sentiment: Pipeline and leadership developments may support the outlook: The FDA approved an IDE for a NanoKnife feasibility study in benign prostatic hyperplasia, while Eric Honroth is set to become president and CEO on November 2, 2026. CEO Appointment
• Neutral Sentiment: Full-year guidance was reiterated: Fiscal 2027 revenue is expected at $336 million to $341 million, slightly above the $337.6 million analyst consensus at the midpoint. EPS guidance of $(0.29) to $(0.24) is broadly in line with the $(0.26) consensus estimate.
• Negative Sentiment: Profitability and liquidity remain risks: The company still reported a GAAP loss, negative net margin and negative return on equity. It used $15.3 million in operating cash during the quarter, leaving $34.0 million in cash at August 31.
• Negative Sentiment: Insider selling may temper sentiment: A senior vice president sold 23,370 shares for approximately $344,000, with no reported insider purchases during the past six months.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.